Overview of the study protocols and statistical analysis plan for the saline versus Plasma-Lyte 148 for intravenous fluid therapy (SPLIT) research program

Sumeet K Reddy, Paul Jeffrey Young, Richard W Beasley, Diane Mackle, Shay P McGuinness, Colin McArthur, Seton J Henderson, Laurence Weinberg, Craig J French, Neil Orford, Michael John Bailey, Rinaldo Bellomo

Research output: Contribution to journalArticleOther

Abstract

Background: 0.9 saline is the most commonly used intravenous (IV) fluid in the world but recent data raise the possibility that, compared with buffered crystalloid fluids such as Plasma-Lyte 148, the administration of 0.9 saline might increase the risk of developing acute kidney injury. Objective: To provide an overview of the study protocols and statistical analysis plan for the six studies making up the (0.9 Saline v Plasma-Lyte 148 for Intravenous Fluid Therapy (SPLIT) research program. Methods: The SPLIT study consists of six integrated clinical trials, including a double-blind, cluster, randomised, double-crossover study in intensive care unit patients, incorporating two nested studies within it; an open-label, before-and-after study in emergency department (ED) patients; a single-centre, double-blind, crossover trial in major surgical patients; and a randomised, double-blind study in ICU patients. All studies focus on biochemical and renal outcomes but will also provide preliminary data on patient-centred outcomes including inhospital mortality and requirements for dialysis. Results and conclusion: The SPLIT study program will provide preliminary data on the comparative effectiveness of using 0.9 saline v Plasma-Lyte 148 for IV fluid therapy in ED, surgical and ICU patients.
Original languageEnglish
Pages (from-to)29 - 36
Number of pages8
JournalCritical Care and Resuscitation
Volume17
Issue number1
Publication statusPublished - 2015

Cite this

@article{fe3df0131bed4f8e991957b5a01a376c,
title = "Overview of the study protocols and statistical analysis plan for the saline versus Plasma-Lyte 148 for intravenous fluid therapy (SPLIT) research program",
abstract = "Background: 0.9 saline is the most commonly used intravenous (IV) fluid in the world but recent data raise the possibility that, compared with buffered crystalloid fluids such as Plasma-Lyte 148, the administration of 0.9 saline might increase the risk of developing acute kidney injury. Objective: To provide an overview of the study protocols and statistical analysis plan for the six studies making up the (0.9 Saline v Plasma-Lyte 148 for Intravenous Fluid Therapy (SPLIT) research program. Methods: The SPLIT study consists of six integrated clinical trials, including a double-blind, cluster, randomised, double-crossover study in intensive care unit patients, incorporating two nested studies within it; an open-label, before-and-after study in emergency department (ED) patients; a single-centre, double-blind, crossover trial in major surgical patients; and a randomised, double-blind study in ICU patients. All studies focus on biochemical and renal outcomes but will also provide preliminary data on patient-centred outcomes including inhospital mortality and requirements for dialysis. Results and conclusion: The SPLIT study program will provide preliminary data on the comparative effectiveness of using 0.9 saline v Plasma-Lyte 148 for IV fluid therapy in ED, surgical and ICU patients.",
author = "Reddy, {Sumeet K} and Young, {Paul Jeffrey} and Beasley, {Richard W} and Diane Mackle and McGuinness, {Shay P} and Colin McArthur and Henderson, {Seton J} and Laurence Weinberg and French, {Craig J} and Neil Orford and Bailey, {Michael John} and Rinaldo Bellomo",
year = "2015",
language = "English",
volume = "17",
pages = "29 -- 36",
journal = "Critical Care and Resuscitation",
issn = "1441-2772",
publisher = "Australasian Medical Publishing Co. Pty Ltd. (AMPCo)",
number = "1",

}

Overview of the study protocols and statistical analysis plan for the saline versus Plasma-Lyte 148 for intravenous fluid therapy (SPLIT) research program. / Reddy, Sumeet K; Young, Paul Jeffrey; Beasley, Richard W; Mackle, Diane; McGuinness, Shay P; McArthur, Colin; Henderson, Seton J; Weinberg, Laurence; French, Craig J; Orford, Neil; Bailey, Michael John; Bellomo, Rinaldo.

In: Critical Care and Resuscitation, Vol. 17, No. 1, 2015, p. 29 - 36.

Research output: Contribution to journalArticleOther

TY - JOUR

T1 - Overview of the study protocols and statistical analysis plan for the saline versus Plasma-Lyte 148 for intravenous fluid therapy (SPLIT) research program

AU - Reddy, Sumeet K

AU - Young, Paul Jeffrey

AU - Beasley, Richard W

AU - Mackle, Diane

AU - McGuinness, Shay P

AU - McArthur, Colin

AU - Henderson, Seton J

AU - Weinberg, Laurence

AU - French, Craig J

AU - Orford, Neil

AU - Bailey, Michael John

AU - Bellomo, Rinaldo

PY - 2015

Y1 - 2015

N2 - Background: 0.9 saline is the most commonly used intravenous (IV) fluid in the world but recent data raise the possibility that, compared with buffered crystalloid fluids such as Plasma-Lyte 148, the administration of 0.9 saline might increase the risk of developing acute kidney injury. Objective: To provide an overview of the study protocols and statistical analysis plan for the six studies making up the (0.9 Saline v Plasma-Lyte 148 for Intravenous Fluid Therapy (SPLIT) research program. Methods: The SPLIT study consists of six integrated clinical trials, including a double-blind, cluster, randomised, double-crossover study in intensive care unit patients, incorporating two nested studies within it; an open-label, before-and-after study in emergency department (ED) patients; a single-centre, double-blind, crossover trial in major surgical patients; and a randomised, double-blind study in ICU patients. All studies focus on biochemical and renal outcomes but will also provide preliminary data on patient-centred outcomes including inhospital mortality and requirements for dialysis. Results and conclusion: The SPLIT study program will provide preliminary data on the comparative effectiveness of using 0.9 saline v Plasma-Lyte 148 for IV fluid therapy in ED, surgical and ICU patients.

AB - Background: 0.9 saline is the most commonly used intravenous (IV) fluid in the world but recent data raise the possibility that, compared with buffered crystalloid fluids such as Plasma-Lyte 148, the administration of 0.9 saline might increase the risk of developing acute kidney injury. Objective: To provide an overview of the study protocols and statistical analysis plan for the six studies making up the (0.9 Saline v Plasma-Lyte 148 for Intravenous Fluid Therapy (SPLIT) research program. Methods: The SPLIT study consists of six integrated clinical trials, including a double-blind, cluster, randomised, double-crossover study in intensive care unit patients, incorporating two nested studies within it; an open-label, before-and-after study in emergency department (ED) patients; a single-centre, double-blind, crossover trial in major surgical patients; and a randomised, double-blind study in ICU patients. All studies focus on biochemical and renal outcomes but will also provide preliminary data on patient-centred outcomes including inhospital mortality and requirements for dialysis. Results and conclusion: The SPLIT study program will provide preliminary data on the comparative effectiveness of using 0.9 saline v Plasma-Lyte 148 for IV fluid therapy in ED, surgical and ICU patients.

UR - http://www-scopus-com.ezproxy.lib.monash.edu.au/record/display.url?eid=2-s2.0-84925300619&origin=resultslist&sort=plf-f&src=s&st1=Overview+of+the+stud

M3 - Article

VL - 17

SP - 29

EP - 36

JO - Critical Care and Resuscitation

JF - Critical Care and Resuscitation

SN - 1441-2772

IS - 1

ER -